Mark N. Wegman is Director at BIOSPECIFICS TECHNOLOGIES CORP (BSTC). They have made 5 open-market trades across 1 company since 2018, most recently 2020-12-02.
CIK 0001405235
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BSTC | SELL | 2019-05-24 | 2019-05-28 | $61.09 | $477K | -6.5% | -3.7% | -8.8% |
| BSTC | SELL | 2019-05-22 | 2019-05-23 | $63.70 | $76K | -5.7% | -6.0% | -4.5% |
| BSTC | SELL | 2019-05-21 | 2019-05-22 | $64.04 | $768K | -9.1% | -6.0% | -6.2% |
| BSTC | SELL | 2018-09-10 | 2018-09-11 | $57.52 | $374K | -3.4% | -4.6% | +1.4% |
| BSTC | SELL | 2018-08-22 | 2018-08-23 | $52.63 | $895K | +7.3% | +15.2% | +10.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.